Official Positions for FRAX® Clinical Regarding Glucocorticoids: The Impact of the Use of Glucocorticoids on the Estimate by FRAX® of the 10 Year Risk of Fracture

被引:55
|
作者
Leib, Edward S. [1 ]
Saag, Kenneth G. [2 ]
Adachi, Jonathan D. [3 ]
Geusens, Piet P. [4 ,5 ]
Binkley, Neil [6 ]
McCloskey, Eugene V. [7 ]
Hans, Didier B. [8 ]
机构
[1] Univ Vermont, Coll Med, Burlington, VT 05401 USA
[2] Univ Alabama Birmingham, Birmingham, AL USA
[3] McMaster Univ, St Josephs Healthcare, Hamilton, ON, Canada
[4] Maastricht Univ Caphri, Dept Internal Med, Fac Hlth Med & Life Sci, Maastricht, Netherlands
[5] Univ Hasselt, Biomed Res Ctr, Hasselt, Belgium
[6] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA
[7] Univ Sheffield, Sheffield, S Yorkshire, England
[8] Univ Lausanne Hosp, Dept Bone & Joint, Lausanne, Switzerland
基金
英国医学研究理事会;
关键词
Glucocorticoids; fracture risk; drug-induced osteoporosis; FRAX; BONE-MINERAL DENSITY; OBSTRUCTIVE PULMONARY-DISEASE; LOW-DOSE PREDNISONE; INHALED CORTICOSTEROIDS; ADDISONS-DISEASE; REPLACEMENT THERAPY; 21-HYDROXYLASE DEFICIENCY; INDUCED OSTEOPOROSIS; ORAL GLUCOCORTICOIDS; RHEUMATOID-ARTHRITIS;
D O I
10.1016/j.jocd.2011.05.014
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Given the significant impact the use of glucocorticoids can have on fracture risk independent of bone density, their use has been incorporated as one of the clinical risk factors for calculating the 10-year fracture risk in the World Health Organization's Fracture Risk Assessment Tool (FRAX (R)). Like the other clinical risk factors, the use of glucocorticoids is included as a dichotomous variable with use of steroids defined as past or present exposure of 3 months or more of use of a daily dose of 5 mg or more of prednisolone or equivalent. The purpose of this report is to give clinicians guidance on adjustments which should be made to the 10-year risk based on the dose, duration of use and mode of delivery of glucocorticoid preparations. A subcommittee of the International Society for Clinical Densitometry and International Osteoporosis Foundation joint Position Development Conference presented its findings to an expert panel and the following recommendations were selected. 1) There is a dose relationship between glucocorticoid use of greater than 3 months and fracture risk. The average dose exposure captured within FRAX (R) is likely to be a prednisone dose of 2.5-7.5 mg/day or its equivalent. Fracture probability is under-estimated when prednisone dose is greater than 7.5 mg/day and is over-estimated when the prednisone dose is less than 2.5 mg/day. 2) Frequent intermittent use of higher doses of glucocorticoids increases fracture risk. Because of the variability in dose and dosing schedule, quantification of this risk is not possible. 3) High dose inhaled glucocorticoids may be a risk factor for fracture. FRAX (R) may underestimate fracture probability in users of high dose inhaled glucocorticoids. 4) Appropriate glucocorticoid replacement in individuals with adrenal insufficiency has not been found to increase fracture risk. In such patients, use of glucocorticoids should not be included in FRAX (R) calculations.
引用
收藏
页码:212 / 219
页数:8
相关论文
共 50 条
  • [1] Official Positions for FRAX® Clinical Regarding Smoking
    Dimai, Hans P.
    Chandran, Manju
    JOURNAL OF CLINICAL DENSITOMETRY, 2011, 14 (03) : 190 - 193
  • [2] Official Positions for FRAX® Clinical Regarding Prior Fractures
    Blank, Robert D.
    JOURNAL OF CLINICAL DENSITOMETRY, 2011, 14 (03) : 205 - 211
  • [3] Official Positions for FRAX® Clinical Regarding Biochemical Markers
    McCloskey, Eugene V.
    Vasikaran, Samuel
    Cooper, Cyrus
    JOURNAL OF CLINICAL DENSITOMETRY, 2011, 14 (03) : 220 - 222
  • [4] Official Positions for FRAX® Clinical Regarding Rheumatoid Arthritis
    Broy, Susan B.
    Tanner, S. Bobo
    JOURNAL OF CLINICAL DENSITOMETRY, 2011, 14 (03) : 184 - 189
  • [5] Official Positions for FRAX® Clinical Regarding International Differences
    Cauley, Jane A.
    El-Hajj Fuleihan, Ghada
    Arabi, Asma
    Fujiwara, Saeko
    Ragi-Eis, Sergio
    Calderon, Andrew
    Chionh, Siok Bee
    Chen, Zhao
    Curtis, Jeffrey R.
    Danielson, Michelle E.
    Hanley, David A.
    Kroger, Heikki
    Kung, Annie W. C.
    Lesnyak, Olga
    Nieves, Jeri
    Pluskiewicz, Wojciech
    El Rassi, Rola
    Silverman, Stuart
    Schott, Anne-Marie
    Rizzoli, Rene
    Luckey, Marjorie
    JOURNAL OF CLINICAL DENSITOMETRY, 2011, 14 (03) : 240 - 262
  • [6] Official Positions for FRAX® Clinical Regarding Falls and Frailty: Can Falls and Frailty be Used in FRAX®?
    Masud, Tahir
    Binkley, Neil
    Boonen, Steven
    Hannan, Marian T.
    JOURNAL OF CLINICAL DENSITOMETRY, 2011, 14 (03) : 194 - 204
  • [7] Potential Impact of Recent Clinical Vertebral Fracture on FRAX 10year Probability
    Johansson, Helena
    Liu, Enwu
    Kanis, John A.
    Siggeirsdottir, Kristin
    Gudnason, Vilmundur
    Sigurdson, Gunnar
    Harvey, Nicholas C.
    McCloskey, Eugene
    Lorentzon, Mattias
    JOURNAL OF BONE AND MINERAL RESEARCH, 2019, 34 : 155 - 155
  • [8] USE OF FRAX® SCALE TO ESTIMATE BONE FRACTURE RISK IN PATIENTS UNDERGOING HAEMODIALYSIS
    Hernandez, Paul
    Sandino Perez, Justo
    Aubert, Lucia
    Gonzalez Garcia, Celia
    Merida, Evangelina
    Gutierrez, Elena
    Pascual, Julio
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 : I395 - I395
  • [9] FRAX™: A new instrument for calculating 10-year absolute fracture risk
    Claus-Hermberg, Haraldo
    Bagur, Alicia
    Messina, Osvaldo D.
    Negri, Armando L.
    Schurman, Leon
    Sanchez, Ariel
    MEDICINA-BUENOS AIRES, 2009, 69 (05) : 571 - 575
  • [10] CAROC and FRAX® say the 10 Year Fracture Risk in Canada similarly well in advance
    Pfeilschifter, Johannes
    OSTEOLOGIE, 2010, 19 (04) : 365 - 366